Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Prostate Cancer

  Free Subscription


27.07.2020

3 BJU Int
1 BMC Urol
1 Cancer
1 Cancer Lett
3 Clin Cancer Res
2 Eur Radiol
2 Eur Urol
1 Int J Radiat Oncol Biol Phys
1 Int J Urol
1 J Nucl Med
7 J Urol
1 Mod Pathol
2 Nat Rev Urol
2 Oncogene
1 PLoS One
2 Proc Natl Acad Sci U S A
1 Prog Urol
2 Prostate
2 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    BJU Int

  1. TEOH JY, Chiong E, Ng CF
    Can artificial intelligence optimize case selection for hemi-gland ablation?
    BJU Int. 2020;125:333-334.
    PubMed        

  2. GLASER ZA, Rais-Bahrami S
    Magnetic resonance imaging as a personalised tool to safely avoid prostate biopsy.
    BJU Int. 2020;125:335-336.
    PubMed        

  3. UCHIMOTO T, Komura K, Fukuokaya W, Kimura T, et al
    Risk Stratification for the Prediction of Overall Survival Could Assists Treatment Decision Making at the Diagnosis of Castration-Resistant Prostate Cancer - a Multicenter Collaborative Study in Japan.
    BJU Int. 2020 Jul 23. doi: 10.1111/bju.15187.
    PubMed         Abstract available


    BMC Urol

  4. ZHAO HW, Li J, Cao JZ, Lin J, et al
    Contrast-enhanced transrectal ultrasound can reduce collection of unnecessary biopsies when diagnosing prostate cancer and is predictive of biochemical recurrence following a radical prostatectomy in patients with localized prostate cancer.
    BMC Urol. 2020;20:100.
    PubMed         Abstract available


    Cancer

  5. XU X, Fallah M, Tian Y, Mukama T, et al
    Risk of invasive prostate cancer and prostate cancer death in relatives of patients with prostatic borderline or in situ neoplasia: A nationwide cohort study.
    Cancer. 2020 Jul 22. doi: 10.1002/cncr.33096.
    PubMed         Abstract available


    Cancer Lett

  6. BATES M, Boland A, McDermott N, Marignol L, et al
    YB-1: The key to personalised prostate cancer management?
    Cancer Lett. 2020 Jul 15. pii: S0304-3835(20)30361.
    PubMed         Abstract available


    Clin Cancer Res

  7. KAUR H, Salles DC, Murali S, Hicks JL, et al
    Genomic and Clinical-Pathologic Characterization of ATM-deficient Prostate Cancer.
    Clin Cancer Res. 2020 Jul 21. pii: 1078-0432.CCR-20-0764.
    PubMed         Abstract available

  8. AGGARWAL RR, Schweizer MT, Nanus DM, Pantuck AJ, et al
    A Phase 1b/2a Study of the Pan-BET Bromodomain Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer.
    Clin Cancer Res. 2020 Jul 21. pii: 1078-0432.CCR-20-1707.
    PubMed         Abstract available

  9. PARK SY, Na SJ, Kumar M, Mosci C, et al
    Clinical evaluation of (4S)-4-(3-[(18)F]Fluoropropyl)-L-glutamate ((18)F-FSPG) for PET/CT imaging in patients with newly diagnosed and recurrent prostate cancer.
    Clin Cancer Res. 2020 Jul 21. pii: 1078-0432.CCR-20-0644.
    PubMed         Abstract available


    Eur Radiol

  10. BERNATZ S, Ackermann J, Mandel P, Kaltenbach B, et al
    Comparison of machine learning algorithms to predict clinically significant prostate cancer of the peripheral zone with multiparametric MRI using clinical assessment categories and radiomic features.
    Eur Radiol. 2020 Jul 16. pii: 10.1007/s00330-020-07064.
    PubMed         Abstract available

  11. HIREMATH A, Shiradkar R, Merisaari H, Prasanna P, et al
    Test-retest repeatability of a deep learning architecture in detecting and segmenting clinically significant prostate cancer on apparent diffusion coefficient (ADC) maps.
    Eur Radiol. 2020 Jul 23. pii: 10.1007/s00330-020-07065.
    PubMed         Abstract available


    Eur Urol

  12. MORIS L, Van den Broeck T, Wiegel T
    Reply to Satoshi Funada, Takashi Yoshioka, and Yan Luo's Letter to the Editor re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: A
    Eur Urol. 2020 Jul 16. pii: S0302-2838(20)30536.
    PubMed        

  13. FUNADA S, Yoshioka T, Luo Y
    Re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Eur Urol 2020;77:614-27.
    Eur Urol. 2020 Jul 15. pii: S0302-2838(20)30517.
    PubMed        


    Int J Radiat Oncol Biol Phys

  14. PALY J, Horwitz EM
    Less Is More: Treatment of Locally Advanced Small Cell Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020;107:865-866.
    PubMed        


    Int J Urol

  15. MARTELL K
    Editorial Comment to High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term androgen deprivation therapy for very high-risk prostate cancer.
    Int J Urol. 2020 Jul 22. doi: 10.1111/iju.14328.
    PubMed        


    J Nucl Med

  16. POMPER MG, Choyke PL
    Discussions with Leaders: A Conversation Between Martin Pomper and Peter Choyke.
    J Nucl Med. 2020;61:3-5.
    PubMed        


    J Urol

  17. STAVRINIDES V, Giganti F, Punwani S, Allen C, et al
    Re: Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?
    J Urol. 2020 Jul 23:101097JU0000000000001295. doi: 10.1097/JU.0000000000001295.
    PubMed        

  18. CARLSSON SV, Touijer K
    Re: Risk of Metastasis in Men with Grade Group 2 Prostate Cancer Managed with AS at a Tertiary Cancer Center.
    J Urol. 2020 Jul 23:101097JU0000000000001292. doi: 10.1097/JU.0000000000001292.
    PubMed        

  19. SHAH N, Ioffe V
    Re: Risk of metastasis in men with Grade Group 2 prostate cancer managed with active surveillance at a tertiary cancer center.
    J Urol. 2020 Jul 23:101097JU0000000000001291. doi: 10.1097/JU.0000000000001291.
    PubMed        

  20. DENIFFEL D, Haider M, Perlis N
    Re: Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?
    J Urol. 2020 Jul 23:101097JU0000000000001296. doi: 10.1097/JU.0000000000001296.
    PubMed        

  21. SPRATT DE
    Editorial Comment.
    J Urol. 2020;204:89-90.
    PubMed        

  22. GRIEBLING TL
    Re: Home-Based 'Exergaming' Was Safe and Significantly Improved 6-Min Walking Distance in Patients with Prostate Cancer: A Single-Blinded Randomised Controlled Trial.
    J Urol. 2020 Jul 23:101097JU000000000000120703.
    PubMed        

  23. TODENHOFER T
    Editorial Comment.
    J Urol. 2020;204:77.
    PubMed        


    Mod Pathol

  24. HOLLEMANS E, Verhoef EI, Bangma CH, Rietbergen J, et al
    Cribriform architecture in radical prostatectomies predicts oncological outcome in Gleason score 8 prostate cancer patients.
    Mod Pathol. 2020 Jul 20. pii: 10.1038/s41379-020-0625.
    PubMed         Abstract available


    Nat Rev Urol

  25. ELDRED-EVANS D, Tam H, Sokhi H, Padhani AR, et al
    Rethinking prostate cancer screening: could MRI be an alternative screening test?
    Nat Rev Urol. 2020 Jul 21. pii: 10.1038/s41585-020-0356.
    PubMed         Abstract available

  26. KOUSPOU MM, Fong JE, Brew N, Hsiao STF, et al
    The Movember Prostate Cancer Landscape Analysis: an assessment of unmet research needs.
    Nat Rev Urol. 2020 Jul 22. pii: 10.1038/s41585-020-0349.
    PubMed         Abstract available


    Oncogene

  27. KOHNO S, Linn P, Nagatani N, Watanabe Y, et al
    Pharmacologically targetable vulnerability in prostate cancer carrying RB1-SUCLA2 deletion.
    Oncogene. 2020 Jul 21. pii: 10.1038/s41388-020-1381.
    PubMed         Abstract available

  28. WHITLOCK NC, Trostel SY, Wilkinson S, Terrigino NT, et al
    MEIS1 down-regulation by MYC mediates prostate cancer development through elevated HOXB13 expression and AR activity.
    Oncogene. 2020 Jul 17. pii: 10.1038/s41388-020-01389.
    PubMed         Abstract available


    PLoS One

  29. WU YT, Chiang PH
    Cohort study of high-intensity focused ultrasound in the treatment of localised prostate cancer treatment: Medium-term results from a single centre.
    PLoS One. 2020;15:e0236026.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  30. HALDAR S, Mishra R, Billet S, Thiruvalluvan M, et al
    Cancer epithelia-derived mitochondrial DNA is a targetable initiator of a paracrine signaling loop that confers taxane resistance.
    Proc Natl Acad Sci U S A. 2020;117:8515-8523.
    PubMed         Abstract available

  31. WASMUTH EV, Hoover EA, Antar A, Klinge S, et al
    Modulation of androgen receptor DNA binding activity through direct interaction with the ETS transcription factor ERG.
    Proc Natl Acad Sci U S A. 2020;117:8584-8592.
    PubMed         Abstract available


    Prog Urol

  32. PLOUSSARD G
    [Prostate cancer].
    Prog Urol. 2020;30.
    PubMed        


    Prostate

  33. FERRARI MG, Ganaie AA, Shabenah A, Mansini AP, et al
    Identifying and treating ROBO1(-ve) /DOCK1(+ve) prostate cancer: An aggressive cancer subtype prevalent in African American patients.
    Prostate. 2020 Jul 20. doi: 10.1002/pros.24018.
    PubMed         Abstract available

  34. NANDA JS, Awadallah WN, Kohrt SE, Popovics P, et al
    Increased nuclear factor I/B expression in prostate cancer correlates with AR expression.
    Prostate. 2020 Jul 21. doi: 10.1002/pros.24019.
    PubMed         Abstract available


    Urology

  35. O'CONNOR LP, Wang AZ, Yerram NK, Lebastchi AH, et al
    Combined MRI-targeted plus systematic confirmatory biopsy improves risk stratification for patients enrolling on active surveillance for prostate cancer.
    Urology. 2020 Jul 14. pii: S0090-4295(20)30828.
    PubMed         Abstract available

  36. MATSUGASUMI T, Shiraishi T, Fujihara A, Ohashi M, et al
    Targeted focal cryoablation for prostate cancer with real-time Transrectal Ultrasound guided free-hands technique: A step-by-step technique.
    Urology. 2020 Jul 16. pii: S0090-4295(20)30847.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: